ACR
Director Trades
| Date | Director | Value |
|---|---|---|
| G. Brooke | $10,000 | |
| D. Brumley | $80,000 | |
| M. Kotsanis | $30,000 | |
| T. Oldham | $10,000 | |
| R. Dobinson | $20,000 |
Company News
Acrux and TruPharma launch generic acne treatment in US market
Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to manage the common skin condition that involves blockage and inflammation of hair follicles and accompanying sebaceous […]
FDA approval paves way for Acrux to launch generic testosterone topical solution in US
Pharmaceutical company Acrux (ASX: ACR) has secured United Stated Food and Drug Administration approval for its generic testosterone topical solution. The topical drug is based on Perrigo’s Testosterone Topical solution which has a dose of 30mg per 1.5mL. Acrux initially submitted an abbreviated new drug application with the FDA in August 2018 to market its […]
ASX-listed pooled development funds offer investors tax benefits
Astute investors weigh up the pros and cons before putting their hard earned money behind a company, and what appeals to people who invest in pooled development funds (PDFs) is the availability of generous tax concessions. PDFs raise capital and make equity investments in small and medium-sized (SMEs) enterprises after complying with a structure established […]
FDA accepts Acrux application for generic version of nail fungus drug Jublia
Pharmaceutical company Acrux (ASX: ACR) is a step closer to commercialising a topical treatment for onychomycosis in the US after this morning’s news that the US Food and Drug Administration (FDA) had accepted Acrux’ “Paragraph IV Abbreviated” new drug application (ANDA) dossier. The acceptance means the Acrux product will be reviewed for approval by the […]
